MATERIALS AND METHODS

The Cohort
The Kaiser Permanente Medical Care Program of Northern California is a health maintenance organization (HMO) caring for about one-quarter of the San Francisco Bay area population. The Program has been described in detail elsewhere. 11, 12 In brief, the 'enrolees' are socioeconomically and ethnically diverse but, on average, their education level is somewhat higher than that of the general population. For the current longitudinal study, the baseline examination consisted of Multiphasic Health Checkups carried out in San Francisco or Oakland between 1977 and 1985. The Multiphasic Health Checkup is a voluntary comprehensive health assessment offered by the plan at the time of enrolment and then yearly. For participants with repeated health examinations, we used data from the first available Multiphasic Health Checkup.
Computerized information on Kaiser membership has been periodically updated since 1976 for all current and past members. At the Multiphasic Health Checkup, members completed questionnaires detailing personal and demographic information (age, gender, race, education level), medical history (including pre-existing medical conditions) and health habits (smoking and alcohol consumption). Physiological data such as weight, height and blood chemistry (in venous blood specimens collected after an 8-hour overnight fast) were also obtained according to standardized procedures. 12 Body mass index was computed as weight (kg) divided by height (m 2 ). Total serum cholesterol was measured at the Kaiser Permanente Regional Laboratory (Berkeley, CA) according to enzymatic methods and calibration standards referenced to the Abell-Kendall method. 13 The total cholesterol values were corrected for measurement deviation. This was done by fitting a trend line to the monthly mean cholesterol (by gender and five age groups) in two periods defined by the use of two different analysers (American Monitor KDA from 1977 to 1982, and the Abbott VP until 1985). Offsets were calculated so as to form a smooth curve across time. The same offset (month-and analyser-specific) was then applied to all individual cholesterol measurements.
Among 144 003 members who had a valid serum cholesterol measurement, those aged 24 or younger (n = 15 762), and those 90 and older (n = 59) were excluded. Among the remaining subjects aged 25-89, 20 393 were excluded for the following nonmutually exclusive self-reported medical conditions at baseline: coronary heart disease (n = 3140), stroke (n = 893), tumour or cancer (n = 6978), history of tuberculosis (n = 2459), history of asthma (n = 7906), history of emphysema (n = 943), or HIV/AIDS (n = 16). Of the remaining 107 789 participants, 4325 were also ineligible because of lack of data on ethnicity, education level, weight or height. These exclusions left 48 188 men and 55 276 women as the sample for statistical analysis. A total of 976 866 person-years of observation were accrued during the 15 years of follow-up (447 415 in men, and 529 451 in women). Those who were excluded for missing data did not differ significantly in age or total serum cholesterol from those who remained in the analysis. The study was approved by the Institutional Review Boards of the Kaiser Foundation Research Institute and the University of Minnesota.
Study Endpoints
The primary endpoints of this study were hospitalizations for respiratory disease (2% in-hospital fatal cases), extracted from a database of up to 12 discharge diagnosis codes per hospitalization. For comparability with previous mortality studies, a secondary set of endpoints consisted of only fatal events (both in-hospital and out-of-hospital), ascertained by the single underlying cause of death by the California Automated Mortality Linkage System (CAMLIS). CAMLIS is a probability linkage system based on name, date of birth, race, place of birth and social security number. CAMLIS has been satisfactorily validated against the National Death Index.
14 Mortality out of the state of California in the Kaiser population has been estimated to be only 2.2%. 14 The follow-up period started 1 January 1979 and ended 31 December 1993. The median length of follow-up time was 9.9 years (range 1-15 years).
The hospitalization records included a unique identification number, the patient's demographics, admission and discharge dates, discharge vital status, and discharge diagnoses. Both the hospital discharge diagnoses and the CAMLIS underlying cause of death were coded using the Ninth Revision of the International Classification of Diseases (ICD-9). Recurrent non-fatal events in the same person were allowed (i.e. an individual could have been hospitalized for asthma, and then for pneumonia some years later). The outcome measures included: 1) pneumonia/influenza (codes 480-487); 2) chronic bronchitis (code 491)/emphysema (code 492)/ related conditions (490, 494-496), the latter including bronchitis not specified as acute or chronic (490), bronchiectasis (494), extrinsic allergic alveolitis (495), and chronic airway obstruction, not elsewhere classified (496); 3) asthma (code 493); and 4) miscellaneous diseases of the respiratory system. Miscellaneous diseases of the respiratory system encompassed infections and inflammatory conditions, as well as conditions which are usually secondary to other major illness. Specifically, miscellaneous conditions included acute respiratory infections (codes 460-466), chronic upper respiratory infections (codes 472-476, 478.21-478.29), allergic rhinitis (code 477), pneumoconioses (codes 500-508), empyema (code 510), abscess of lung (code 513), mediastinitis (code 519.2), pleurisy other than tuberculosis (code 511), pulmonary congestion and hypostasis (code 514), post-inflammatory pulmonary fibrosis (code 515), other alveolar and parieto-alveolar pneumopathy (code 516), lung involvement in conditions classified elsewhere (code 517), and pulmonary collapse (code 518). The following other respiratory diseases were expected to be unrelated to the level of serum cholesterol, and thus were not considered: deviated nasal septum (code 470), nasal polyps (code 471), other diseases of upper respiratory tract (code 478, except 478.21-478.29), spontaneous pneumothorax (code 512), and other diseases of respiratory system (519). The lack of an association between these other conditions and serum cholesterol was verified (data not shown). The total number of occurrences of each of the respiratory disease discharge diagnoses and deaths are given in the tables pertinent to each outcome variable.
Statistical Analysis
The Cox proportional hazards model 15 was used to determine the sex-specific risk relation between serum total cholesterol and respiratory diseases. First, to assess the presence of linear trends, each respiratory outcome was modelled as a function of a continuous cholesterol term, age and covariates; the resulting hazard rate ratios were expressed per 1.187 mmol/l, the standard deviation of cholesterol for all participants combined. Multivariate-adjusted relative risks and associated 95% confidence intervals were then calculated for the following serum total cholesterol categories: Ͻ4.14 mmol/l (Ͻ160 mg/dl), 4.14-5.15 mmol/l (160-199 mg/dl) (referent level, i.e. relative risk = 1), 5.16-6.19 mmol/l (200-239 mg/dl), and у6.20 mmol/l (у240 mg/dl). The covariates included: race (black, Asian, and other, relative to white), educational level as a proxy of socioeconomic status (at least some college education versus lower than a college education), body mass index, smoking status (former, current, relative to never smokers), and alcohol consumption (former, occasional-light-moderate [р2 drinks/day], and high [у3 drinks/day], relative to abstainers). Length of follow-up was estimated for each participant as time from the Multiphasic Health Checkup to event, to loss of follow-up (end of membership), or to closing date (31 December 1993), whichever came first. The assumption of proportionality of the Cox model (i.e. that the ratio of hazards is constant over time) was checked by visual inspection of survival plots and by including sex-specific interaction terms of serum cholesterol by time. Because the proportionality assumption did not hold in many instances (indicating decay of the hazard ratio over time, data not shown), all analyses were also run excluding the first 5 years of follow-up.
Effect modification of the serum cholesterolrespiratory disease relationships was studied by fitting interactions terms: linear serum cholesterol × dichotomous age (i.e. 25-54 = 0; 55-89 = 1), and linear serum cholesterol × smoking status (i.e. never = 0; ever = 1), separately for men and women. To see the extent to which the associations of serum cholesterol level with respiratory outcomes differed across age groups and smoking status, cholesterol stratum-specific risk estimates were obtained in younger (25-54 years old) and older (55-89 years old) study participants; and for never and ever (former or current) smokers.
All analyses were undertaken using SAS software (version 6.11, SAS Inc. Cary, North Carolina) on a SUN Workstation (Sun Microsystems, San Francisco, CA). P-values are reported as a general guide to statistical significance. However, these P-values should be interpreted with some caution because of the large number of comparisons made in this study.
RESULTS
The baseline characteristics of the cohort are given in Table 1 . The mean age was 42 years, and the median age was 39 years. Approximately 22% of the sample were 55 years of age or older, 7% were 65 or older, and 60% were white. Men had a higher education level, and higher proportion of heavy smokers (у20 cigarettes/ day) and high alcohol consumption (у3 drinks/day) than women. About 17% of both genders self-reported hypertension.
The percentage of men with a total cholesterol level Ͻ4.14 mmol/l (160 mg/dl) decreased with age in both genders ( Table 2 ). In men aged 25-54, 14% had a total cholesterol concentration Ͻ4.14 mmol/l, while in men aged 55 and older the percentage falling in this total cholesterol category was 4%. Among younger women (25-54), 17% had a total cholesterol level Ͻ4.14 mmol/l. By age 55 or above, the percentage in the lowest cholesterol group diminished to 2%.
In men, a statistically significant inverse association was found between serum cholesterol and hospitalization for pneumonia/influenza (Table 3) . Risk was reduced by about 10% per standard deviation increase of cholesterol, about 9% after excluding events in the first 5 years of follow-up. Exclusion of these early events resulted in lower relative risk for those with cholesterol Ͻ4.14 mmol/l, but had little impact on the negative gradient across higher cholesterol categories. In all age and smoking subgroups, for both 'all followup' and excluding those who died in the first 5 years, the lowest risk was seen in those whose cholesterol was у6.20 mmol/l. Risk reduction with increasing cholesterol was stronger in older than younger men (P = 0.0009 for interaction) and in ever smokers than in never smokers (P = 0.22 for interaction). In women, there was also reduced risk of hospitalization for pneumonia/influenza with increasing cholesterol, but it was weaker than in men and inconsistent across subgroups. Similar to men, a risk reduction of about 10% per standard deviation increase of cholesterol was seen in older women and in women who had never smoked. Contrary to expectation, there was a statistically significant positive association in younger women and in women who had ever smoked.
There was a non-statistically significant inverse association between serum total cholesterol and hospitalization for chronic bronchitis/emphysema related conditions among men, which was more pronounced in younger men and in ever smoking men (Table 4) . Among women, no clear pattern was seen.
No associations were found between serum total cholesterol and risk of hospitalization for asthma in any sex-or age-smoking subgroups (Table 5) .
There was a reduced risk for hospitalization for 'miscellaneous' respiratory diseases of about 11% per standard deviation increase of cholesterol in men ( Table 6 ). This reduced risk persisted when the analysis was repeated excluding events in the first 5 years of follow-up, reflecting substantial attenuation of excess risk in the relatively few men with low cholesterol, compensated by decreased risk in those with higher cholesterol levels. However, this persistent inverse association, about a 20% risk reduction per standard deviation of cholesterol, was confined to older men (negative interaction between serum total cholesterol and age in men, P = 0.0001). This inverse pattern of risk was observed in both smoking groups. In women, the relationship between serum total cholesterol and 'miscellaneous' diseases of the respiratory system also tended to be inverse, but was not monotonic and did not achieve statistical significance (Table 6) .
We also developed models focusing solely on fatal events as ascertained by the CAMLIS (Table 7) . No association was seen between serum total cholesterol and pneumonia/influenza as underlying cause of death. A significant inverse association, about a 25% risk reduction per standard deviation, existed between serum cholesterol and deaths attributed to COPD and allied conditions in men, due to a lower risk at the higher cholesterol concentrations. A similar but not statistically significant pattern, with a risk reduction of 16% per standard deviation of cholesterol, was seen in women. Risk reductions of 10-15% per standard deviation increase of cholesterol were seen in men and women for miscellaneous respiratory diseases as underlying cause of death. This level of risk reduction did not achieve statistical significance even though it was comparable to the risk reduction seen in hospitalized events. Exclusion of early deaths did not materially alter these findings. Numbers of deaths did not allow for further stratification by age or smoking status.
DISCUSSION
This study examined a possible epidemiological link between low levels of serum cholesterol and increased risk of respiratory disease in a Health Maintenance Organization cohort. Interest in this association was stimulated by earlier reports of higher than expected noncardiovascular mortality (including deaths due to respiratory causes) among those with low serum cholesterol level in prospective studies. [2] [3] [4] These early reports were usually limited to middle-aged men and assessed only fatal outcomes. We sought here to expand these studies by investigating the relationship between serum cholesterol level and subsequent hospitalizations and mortality due to respiratory diseases in men and women across a wide age range (i.e. 25-89 years), in both smokers and non-smokers.
Overall, the present study shows inverse but inconsistent associations between serum total cholesterol level and risk of hospitalization or death for respiratory diseases across disease types, sexes, age groups and smoking status. Hospitalization for pneumonia/influenza was inversely associated with serum cholesterol level in men and older women, but (contrary to hypothesis) positively related in younger women, while death due to pneumonia/influenza was unrelated to serum cholesterol. Hospitalization for chronic bronchitis/ emphysema-related conditions appeared to be unrelated to serum total cholesterol in women and was weakly inversely associated in men, but death due to chronic bronchitis/emphysema-related conditions was inversely associated with serum cholesterol level in both men and women. No association existed between serum total CHOLESTEROL AND RESPIRATORY DISEASE 1195 Interactions (all deaths included): linear serum cholesterol X dichotomous age (0 = 25-54, 1 = 55-89): P = 0.0009 in men; P = 0. 0001 in women; linear serum cholesterol X smoking status (0 = never, 1 = ever): P = 0.22 in men; P = 0.60 in women. Interactions (all deaths included): linear serum cholesterol X dichotomous age (0 = 25-54, 1 = 55-89): P = 0.07 in men; P = 0. 002 in women; linear serum cholesterol X smoking status (0 = never, 1 = ever): P = 0.51 in men; P = 0.32 in women. a Adjusting for age, race, educational level, body mass index, systolic blood pressure, smoking, and alcohol intake. b In parentheses, number of events after excluding events in the first 5 years of follow-up. c RR = Multivariate-adjusted relative risk, in parentheses, associated 95% confidence interval. Interactions (all deaths included): linear serum cholesterol X dichotomous age (0 = 25-54, 1 = 55-89): P = 0.31 in men; P = 0. 08 in women; linear serum cholesterol X smoking status (0 = never, 1 = ever): P = 0.68 in men; P = 0.85 in women. ICD-9  codes 472-476, 478.21-478.29, 477, 500-508, 510, 513, 519.2, 511, 514-518) by level of total serum cholesterol, according to cholesterol and hospitalization for asthma. Hospitalization for miscellaneous respiratory diseases was inversely related to serum total cholesterol in men, but not women, but deaths were inversely associated with serum cholesterol in both genders. Smoking had inconsistent modifying effects on these associations. Inconsistencies in the associations of serum cholesterol with respiratory diseases have been seen in other studies. Low serum cholesterol was not a predictive factor of non-cardiovascular disease mortality in young adult men. 16 In the analysis of 350 977 men aged 35-57 years screened for the Multiple Risk Factor Intervention Trial, 2 there was an inverse and graded association between serum cholesterol level and COPD mortality, significantly stronger among cigarette smokers than nonsmokers. An inverse graded relationship between serum cholesterol concentration and all respiratory mortality, and for bronchitis and pneumonia mortality separately, was also reported in the Whitehall Study of male civil servants aged 40-64 years. Because a graded association has been reported, 1, 2 we focused on the linear trend. There has also been considerable interest in risk associated with absolutely low cholesterol, 1,2 so we also examined serum cholesterol in categories. The linear trends usually fit the categorical risks well. Given risk instability due to limited numbers with low cholesterol in those aged 55+, and limited numbers of some respiratory diseases in never smokers, assumption of a linear trend may be necessary to make sense of the data. It is of interest thatrisk is often lowest in the highest of the serum cholesterol categories.
Three interpretations are possible of these findings of inverse associations between serum cholesterol level and risk of hospitalization and death for respiratory disease in subgroups. These interpretations are not mutually exclusive. First, the findings may be spurious, due to lack of adjustment for confounding factors not measured in the study. Factors that may explain these associations are the lipid soluble vitamins (vitamin E and carotenoids), which strongly correlate with cholesterol levels, [17] [18] [19] and are thought to have immunoregulatory properties. 20, 21 Moreover, these micronutrients may inhibit peroxidation of membrane lipids and thus may protect the lungs from oxidative injury. 22 Second, because some of the inverse associations weakened when events within 5 years of baseline were excluded (more clearly in the case of pneumonia/influenza), reverse causality is another plausible explanation. According to this mechanism, serum total cholesterol is lowered by the wasting syndrome associated with the disease. Finally, several lines of evidence suggest a possible aetiological role of cholesterol in the development of respiratory disease. Since cholesterol is a component of pulmonary surfactant (along with phospholipids, triglycerides, free fatty acids and specific apoproteins), 23 it has been suggested that low circulating levels of cholesterol could impair the characteristics and function of pulmonary surfactant. 24 Second, there is evidence of a role of HDL as an anti-inflammatory agent. 25 Finally, there is experimental evidence that circulating lipoproteins bind to infectious agents, 26 and may thereby ameliorate effects of endotoxins. 27 In any case, how low cholesterol level might contribute to susceptibility to respiratory disease remains speculative.
Both the Multiple Risk Factor Intervention Trial 2 and the Whitehall Study 4 concluded that low serum cholesterol may be a marker of recurrent infections and chronic inflammatory changes with associated increases in cytokines. Supporting this interpretation is the evidence that the acute phase reaction lowers plasma lipoprotein cholesterol. 28 Limitations in the current study include: the absence of measurements of cholesterol lipoprotein subfractions, the lack of assessment of habitual macro-and micronutrient intake, the problem of regression toward the mean in single physiological determinations, leading to regression dilution bias 29 and the inability to make the important distinction between long-standing low cholesterol levels and recently acquired hypocholesterolaemia. 7, 28 Although the large sample size is a strength, and affords an opportunity to study the influence of gender, age and smoking on observed associations (thus enhancing the generalizability of our findings), statistical power is substantially lower for deaths than for hospitalizations, and is limited for some subgroups. Another strength is the ability to evaluate prospectively the relationship between serum cholesterol level and subsequent respiratory morbidity as well as mortality.
Regardless of the mechanisms for the observed inverse associations between cholesterol and respiratory disease, the public health significance of high serum cholesterol far outstrips that of low serum cholesterol. Even assuming that the observed relationships are to some extent causal, reduction of the burden of coronary disease achievable by cholesterol reduction would clearly outweigh the hypothetical increased respiratory disease risk.
In summary, associations of serum cholesterol levels with increased risk of hospitalization and death by respiratory diseases were inverse, but subject to considerable inconsistency. Clarification of the biological mechanisms explaining the observed associations is beyond the scope of this study. To obtain a better understanding of the reasons behind the relation between low cholesterol and respiratory disease, future epidemiological studies on this topic should incorporate measures of acute phase reactants and antioxidant status.
